

CANTATA: Randomized, global, double-blind study of telaglenastat (CB-839) plus cabozantinib vs. cabozantinib plus placebo in patients with metastatic renal cell carcinoma


Nizar Tannir¹, Neeraj Agarwal², Nancy Dawson³, Robert Motzer⁴, Carmel Jacobs⁵, Toni Choueiri⁶, John Hrom⁷, Daniel M. Geynisman⁸, Nancy Davis⁹, Robert Figlin¹⁰, Mary O'Keeffe¹¹, Jigarkumar Parikh¹², Daniel Vaena¹³, Ping-Yu Liu¹⁴, Bridget O'Keeffe¹⁵, Xuan Tran¹⁵, Bernard Escudier¹⁶

¹The University of Texas MD Anderson Cancer Center, Houston, TX; ²Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; ³Georgetown University Lombardi Comprehensive Cancer Center, Washington, D.C.; ⁴Memorial Sloan Kettering Cancer Center, New York, NY; ⁵Auckland City Hospital, Auckland, NZ; ⁶Dana Farber Cancer Institute, Boston, MA; ⁷Forrest General Cancer Center, Hattiesburg, MS; ⁸Fox Chase Cancer Center, Philadelphia, PA; ⁹Vanderbilt Ingram Cancer Center, Nashville, TN; ¹⁰Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA; ¹¹Winthrop University Hospital, Mineola, NY; ¹²Medical College of Georgia, Augusta, GA; ¹³The West Clinic, Memphis, TN; ¹⁴Fred Hutchinson Cancer Research Center, Seattle, WA; ¹⁵Calithera Biosciences Inc., South San Francisco, CA; ¹⁶Gustave Roussy, Villejuif, France

BACKGROUND

Glucose and Glutamine Metabolism in Tumors

Figure 1. Targeting Cancer Cell Metabolism



- **Glucose and glutamine** are key nutrients that fuel cancer cell proliferation and survival through the production of energy (ATP) and biosynthetic intermediates (amino acids, nucleotides, fatty acids)
- **Glutaminase (GLS)** controls glutamine utilization (converting glutamine to glutamate) while **growth factor signaling** pathways regulate glucose utilization

Rationale for Combination of CB-839 and Cabozantinib


- Renal cell carcinoma (RCC) expresses high levels of GLS,¹ and RCC cells are sensitive to telaglenastat (CB-839), a first-in-clinic, oral, selective, potent inhibitor of GLS²
- In preclinical studies, combination of CB-839 with the signal transduction inhibitor cabozantinib:²
 - Inhibited glucose and glutamine metabolic pathways
 - Had synergistic antiproliferative activity *in vitro*
 - Showed enhanced anti-tumor activity in mouse xenograft models

Clinical Experience with CB-839 + Cabozantinib

- In a Phase 1 dose escalation/dose expansion study of CB-839 (NCT02071862), CB-839 + cabozantinib demonstrated encouraging clinical activity and tolerability in heavily pre-treated patients with clear cell metastatic RCC (mRCC)³⁻⁵
 - 50% overall response rate (ORR)
 - 100% disease control rate (DCR)

STUDY DESIGN

Figure 2. Study Schema (NCT03428217)



- **Stratification**
 - Prior PD-1/PD-L1 inhibitor therapy
 - IMDC prognostic risk group
- **Study Locations:** US, France, UK, Spain, Italy, Germany, Australia, New Zealand
- **Study Status:** Enrolling

Statistical Design

Sample Size	416
Power	85%
Alpha	0.05 (two-sided)
Hazard Ratio	0.69

STUDY ENDPOINTS

Primary Endpoint: progression-free survival (PFS) per RECIST v1.1 by blinded independent review committee (IRC)

Secondary Endpoints

- Overall survival (OS)
- Investigator-assessed PFS

Other Endpoints

- Overall response rate (ORR), duration of response (DOR), disease control rate, per RECIST v1.1
- Safety and tolerability
- Pharmacokinetics, biomarker analyses, and quality of life

KEY ELIGIBILITY CRITERIA

Inclusion Criteria

- Documented histological or cytological diagnosis of RCC with clear cell component
- Karnofsky performance status $\geq 70\%$
- Measurable disease (RECIST v1.1)
- 1 or 2 prior lines systemic therapy including at least 1 anti-angiogenic therapy or combination of nivolumab + ipilimumab*

Exclusion Criteria

- Prior CB-839 or cabozantinib (or other MET inhibitor)
- Active and/or untreated CNS disease
- Major surgery within 6 weeks or clinically significant bleeding within 3 months before first dose
- Unable to receive oral medications or condition that may prevent adequate absorption of oral study medication
- Inability to discontinue proton pump inhibitor therapy before randomization

SUMMARY

- CB-839 is a first-in-clinic oral inhibitor of GLS, a metabolic enzyme that controls glutamine utilization
- CB-839 synergizes with cabozantinib, an inhibitor of growth factor signaling, to inhibit RCC in preclinical studies
- CB-839 + cabozantinib resulted in a 50% ORR and 100% DCR in heavily pretreated, clear cell mRCC patients
- CANTATA is a phase 2, randomized, global, registrational trial
 - Cabozantinib \pm CB-839
 - Patients with mRCC in 2nd or 3rd line of therapy
 - Following prior anti-VEGF and/or immunotherapy
- Study is currently enrolling

REFERENCES: 1. Cancer Genome Atlas Research Network. *Nature*. 2013;499(7456):43–9; 2. Emberley E, et al. Keystone Symposia on Tumor Metabolism. March 5-9, 2017. Whistler, BC, Canada; 3. Meric-Bernstam F, et al. ASCO Annual Meeting. June 3-7, 2016. Chicago, IL; 4. Tannir N, et al. Genitourinary Cancers Symposium. February 8-10, 2018. San Francisco, CA. 5. Meric-Bernstam F, et al. Genitourinary Cancers Symposium. February 14-16, 2019. San Francisco, CA.

ACKNOWLEDGMENTS: We thank the patients and families, investigators, and coordinators for participation in the study. Ingrid Koo, PhD, provided editorial support for the poster.

